Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells

T. Suzuki, B. Anderegg, T. Ohkawa, A. Irie, O. Engebraaten, M. Halks-Miller, P. S. Holm, D. T. Curiel, M. Kashani-Sabet, K. J. Scanlon

Research output: Contribution to journalArticlepeer-review

65 Scopus citations

Abstract

HER-2/neu is overexpressed in 25-30% of human breast cancers. We prepared an anti-HER-2/neu hammerhead ribozyme expressed by a recombinant adenovirus (rAdHER-Rz). Human breast cancer cell lines were transduced with high efficiency, resulting in decreased HER-2/neu expression. In vivo injections of rAdHER-Rz into BT-474 tumors established in nude mice inhibited tumor growth to 20% of mock-treated controls. Similar in vivo effects were shown in MCF-7 cells, which do not overexpress HER2/neu. The growth inhibitory effects of rAdHER-Rz were greater than those of an antisense-expressing vector These results suggest the utility of anti-HER-2/neu ribozymes as a rational strategy for gene therapy of breast cancer.

Original languageEnglish
Pages (from-to)241-248
Number of pages8
JournalGene therapy
Volume7
Issue number3
DOIs
StatePublished - Feb 2000

Keywords

  • BT-474
  • Gene therapy
  • HER-2/neu
  • Recombinant adenovirus
  • Ribozymes

Fingerprint

Dive into the research topics of 'Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells'. Together they form a unique fingerprint.

Cite this